JWH-019 is an analgesic chemical from the naphthoylindole family that acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It is the N-hexyl homolog of the more common synthetic cannabinoid compound JWH-018. Unlike the butyl homolog JWH-073, which is several times weaker than JWH-018, the hexyl homolog is only slightly less potent, although extending the chain one carbon longer to the heptyl homolog JWH-020 results in dramatic loss of activity. These results show that the optimum side chain length for CB1 binding in the naphthoylindole series is the five-carbon pentyl chain, shorter than in the classical cannabinoids where a seven-carbon heptyl chain produces the most potent compounds. This difference is thought to reflect a slightly different binding conformation adopted by the naphthoylindole compounds as compared to the classical cannabinoids, and may be useful in characterizing the active site of the CB1 and CB2 receptors.
Legal status
China
As of October 2015 JWH-019 is a controlled substance in China.
Poland In Poland, JWH-019 is I-N (Poland).
Sweden JWH-019 is illegal in Sweden.
United Kingdom JWH-019 is Class B in the United Kingdom.
United States JWH-019 is a Schedule I controlled substance, controlled federally in the United States.Controlled Substances listed by the DEA
Germany JWH-019 has been classified under the BtMG as Anlage II.
See also JWH-007 JWH-018 JWH-073 JWH-200 List of JWH cannabinoids
References